Pharsight

Tekturna generic

Tekturna is an antihypertensive drug owned by Noden Pharma. The active ingredient in Tekturna is aliskiren hemifumarate. Tekturna was first made available on the market on 5 March, 2007.

When will Tekturna generic be available?

The generic version of Tekturna is possible to be released after 19 August, 2026. This is due to the expiry of the last patent, US8617595*PED titled 'Galenic formulations of organic compounds', on 19 August, 2026.

Tekturna uses

Tekturna is used to treat high blood pressure. The active ingredient, aliskiren hemifumarate, works by decreasing substances in the body that narrow blood vessels and raise blood pressure.

Tekturna patent expiration

Tekturna has a total of 2 patents. The last of these patents, US8617595*PED titled 'Galenic formulations of organic compounds', will expire on 19 August, 2026, after which the Tekturna generic could potentially be released. Below are the details of the patent:

Tekturna dosage

Want to ask something?